Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Similar articles for PubMed (Select 21664678)

1.

Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.

Hargreaves JR, Greenwood B, Clift C, Goel A, Roemer-Mahler A, Smith R, Heymann DL.

Lancet. 2011 Nov 26;378(9806):1885-93. doi: 10.1016/S0140-6736(11)60687-9. Epub 2011 Jun 12. Review.

PMID:
21664678
2.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
3.

Impact of state vaccine financing policy on uptake of heptavalent pneumococcal conjugate vaccine.

Stokley S, Shaw KM, Barker L, Santoli JM, Shefer A.

Am J Public Health. 2006 Jul;96(7):1308-13. Epub 2006 May 30.

4.

Influence of insurance status and vaccine cost on physicians' administration of pneumococcal conjugate vaccine.

Davis MM, Ndiaye SM, Freed GL, Kim CS, Clark SJ.

Pediatrics. 2003 Sep;112(3 Pt 1):521-6.

PMID:
12949277
5.

The Meningitis Vaccine Project.

LaForce FM, Konde K, Viviani S, Préziosi MP.

Vaccine. 2007 Sep 3;25 Suppl 1:A97-100. Epub 2007 May 7.

PMID:
17521780
6.

Can we defeat meningococcal disease in low and middle income countries?

Greenwood B, Chiarot E, MacLennan CA, O'Ryan M.

Vaccine. 2012 May 30;30 Suppl 2:B63-6. doi: 10.1016/j.vaccine.2011.12.063. Review.

PMID:
22607901
7.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
8.

Global practices of meningococcal vaccine use and impact on invasive disease.

Ali A, Jafri RZ, Messonnier N, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta Z, Abramson J.

Pathog Glob Health. 2014 Jan;108(1):11-20. doi: 10.1179/2047773214Y.0000000126. Review.

9.

Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.

Peny JM, Gleizes O, Covilard JP.

Vaccine. 2005 Aug 31;23(37):4610-8.

PMID:
15979769
10.

Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.

Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE; Active Bacterial Core Surveillance Team.

Clin Infect Dis. 2008 Jan 1;46(1):1-13. doi: 10.1086/524041.

11.

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.

Eur J Health Econ. 2008 Feb;9(1):7-15. Epub 2007 Mar 2.

PMID:
17333089
12.
13.

Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).

Le Gargasson JB, Breugelmans JG, Mibulumukini B, Da Silva A, Colombini A.

Vaccine. 2013 Apr 8;31(15):1886-91. doi: 10.1016/j.vaccine.2013.02.024. Epub 2013 Feb 24.

PMID:
23462529
14.

The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.

Alexander PG, Chartrand SA, Davies TJ, Gaines BM, Oster G, Shurin P, Tamsky L, Thornton DK, Wittert W.

Manag Care Interface. 2001;Suppl C:10-28; quiz 29-30. Review. No abstract available.

PMID:
11724029
15.

Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.

Moore D, Bigham M, Patrick D.

Can Commun Dis Rep. 2003 Jun 1;29(11):97-104. English, French. No abstract available.

16.

[Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].

Gendrel D.

Arch Pediatr. 2012 Sep;19 Suppl 2:S70-6. doi: 10.1016/S0929-693X(12)71277-0. French.

PMID:
22883370
17.

Reducing the dangers of pediatric pneumococcal disease with a new vaccine.

Toth S, Davis RH Jr, Donnelly RE, Leger MM, Muma RD, Taft JM.

JAAPA. 2001 Feb;14(2):58-9. No abstract available.

PMID:
11523192
18.

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ.

Pharmacoeconomics. 2006;24(2):141-53.

PMID:
16460135
19.

Economic evaluation of pneumococcal conjugate vaccination in The Gambia.

Kim SY, Lee G, Goldie SJ.

BMC Infect Dis. 2010 Sep 3;10:260. doi: 10.1186/1471-2334-10-260.

20.

TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.

Clark A, Jauregui B, Griffiths U, Janusz CB, Bolaños-Sierra B, Hajjeh R, Andrus JK, Sanderson C.

Vaccine. 2013 Jul 2;31 Suppl 3:C19-29. doi: 10.1016/j.vaccine.2013.05.045.

PMID:
23777686
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk